NCT01948141View on ClinicalTrials.gov

Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 30, 2014

Primary Completion Date

August 16, 2016

Study Completion Date

August 16, 2016

Conditions
Recurrent Non-small Cell Lung CancerSquamous Cell Lung CancerStage III Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Interventions
DRUG

nintedanib

Given PO

Trial Locations (2)

14263

Roswell Park Cancer Institute, Buffalo

44106

University Hospitals Case Medical Center, Cleveland

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Boehringer Ingelheim

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER

NCT01948141 - Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens | Biotech Hunter | Biotech Hunter